Swedish Orphan Biovitrum Hosts Capital Market Day Event - Announces Phase I Complement Inhibitor Programs

Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial. The company also shared information regarding phase III data for Kepivance® recently acquired from Amgen. These updates as well as expectations for top line data for Kiobrina early next year were provided today at the company's Capital Markets Event in Stockholm.

Help employers find you! Check out all the jobs and post your resume.